Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Optic Neuropathy Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Optic Neuropathy Overview | 8 | 1 |
| Pipeline Products for Optic Neuropathy Comparative Analysis | 9 | 1 |
| Optic Neuropathy Therapeutics under Development by Companies | 10 | 1 |
| Optic Neuropathy Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Optic Neuropathy Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Optic Neuropathy Products under Development by Companies | 15 | 1 |
| Optic Neuropathy Products under Investigation by Universities/Institutes | 16 | 1 |
| Optic Neuropathy Companies Involved in Therapeutics Development | 17 | 7 |
| Amgen Inc. | 17 | 1 |
| BioAxone BioSciences, Inc. | 18 | 1 |
| Inotek Pharmaceuticals Corporation | 19 | 1 |
| Ironwood Pharmaceuticals, Inc. | 20 | 1 |
| PharmatrophiX, Inc. | 21 | 1 |
| Quark Pharmaceuticals, Inc. | 22 | 1 |
| Regenera Pharma Ltd. | 23 | 1 |
| Optic Neuropathy Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 21 |
| BA-240 Drug Profile | 33 | 1 |
| IWP-953 Drug Profile | 34 | 1 |
| LM-22A4 Drug Profile | 35 | 1 |
| Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy Drug Profile | 36 | 1 |
| NT-501 Drug Profile | 37 | 3 |
| QPI-1007 Drug Profile | 40 | 2 |
| RPh-201 Drug Profile | 42 | 2 |
| Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy Drug Profile | 44 | 1 |
| Small Molecules for CNS Disorders and Ophthalmology Drug Profile | 45 | 1 |
| Small Molecules for Neurological and Ophthalmological Diseases Drug Profile | 46 | 1 |
| Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Drug Profile | 47 | 2 |
| Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy Drug Profile | 49 | 1 |
| trabodenoson Drug Profile | 50 | 3 |
| WSTB-1 Drug Profile | 53 | 1 |
| Optic Neuropathy Dormant Projects | 54 | 1 |
| Optic Neuropathy Product Development Milestones | 55 | 3 |
| Featured News &Press Releases | 55 | 1 |
| Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant | 55 | 1 |
| Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India | 55 | 1 |
| Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting | 56 | 1 |
| Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications | 56 | 1 |
| Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION | 57 | 1 |
| Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy | 57 | 1 |
| Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies | 57 | 1 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |